Immature platelet fraction in patients infected with COVID-19

White blood cell parameters in COVID-19 infection

Platelet parameters in COVID-19 infection

Role of hematological parameters and biochemical markers as a predictor of severity of COVID-19 patients

Background: The etiological agent for pandemic COVID-19 is severe acute respiratory syndrome corona virus 2. Hematological and biochemical parameters are the indicators of inflammation and coagulopathy. Aims and Objectives: The present study aimed to determine how effectively the hematological parameters and biochemical markers can help predict the severity of critically ill COVID-19 patients. Materials and Methods: The current retrospective cohort study was conducted among 200 COVID-19 patients admitted in the Sanjay Gandhi Memorial Hospital, Rewa, Madhya Pradesh, India. In our lab’s computerized system, certain hematological and biochemical parameters of the patients were retrieved and recorded. Receiver operating characteristics (ROC) curve analysis was done to evaluate the diagnostic accuracy of hematological and biochemical parameters. Results: Total leukocyte count (TLC), absolute lymphocyte count (ALC), neutrophil to lymphocyte ratio (NLR), D-dimer, and serum ferritin had a significant relationship with severity among ICU patients (P<0.05). ALC, D-dimer, and serum ferritin can be used to predict the severity of COVID patients with area under the ROC-AUC curve values of 0.717, 0.725, and 0.710, respectively. Platelet to lymphocyte ratio, lymphocyte to monocyte ratio, and C-reactive protein were not useful to predict the severity of COVID illness. Conclusion: Hb concentration, TLC, NLR, D-dimer, and serum ferritin were significantly raised in critically ill COVID patients. ROC curve analysis showed that ALC, serum ferritin, and D-dimer were able to predict the severity of COVID illness effectively. Conclusively, these parameters can be used to track the prognosis of patients. [ FROM AUTHOR] Copyright of Asian Journal of Medical Sciences is the property of Manipal Colleges of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Outcomes Following SARS-CoV-2 Infection in Patients With Primary and Secondary Immunodeficiency in The United Kingdom (preprint)

Purpose: To define the burden of morbidity and mortality arising from COVID-19 in individuals with primary (PID) and secondary immunodeficiency (SID) in the United Kingdom. Methods In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. Anonymised demographic data, pre-SARS-CoV-2 infection lymphocyte counts, co-morbidities, targeted treatments and outcomes were collected. Three groups were analysed in further detail: individuals with common variable immunodeficiency (CVID), individuals with any PID, including CVID, receiving immunoglobulin replacement therapy (IgRT) and individuals with secondary immunodeficiency. Results A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID, had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Conclusion Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count and the presence of co-morbidities are additional risk factors for poor outcome in this cohort.

Psychological impact of COVID-19 pandemic on health-care professionals in India - a multicentric cross-sectional stud

Objectives: The world is grappling with an ongoing COVID-19 pandemic that has shaken the mankind to the core and disrupted the lives of everyone. The aim of the study was to assess the presence of psychological distress, depression, anxiety, stress, and insomnia experienced by the Indian healthcare workers. Material and Methods: A cross-sectional study was conducted in India among 777 doctors to evaluate the mental health of doctors working in Corona wards from April 2020 to May 2020 using a pre-designed, pre-tested validated, semi-structured DASS-21 questionnaire, and the Insomnia Severity Index. Continuous variables between the groups were measured using the Mann-Whitney U-test and the Kruskal-Wallis H test.

Molecular Pathogenesis and Treatment Approaches of COVID-19 – A Comprehensive Review (preprint)

An outbreak of “Pneumonia of Unknown Etiology” occurred in Wuhan, China in late December 2019. Later the agent factor was identified and coined as SARS-COV-2 and the disease was named as coronavirus disease 2019 (COVID-19). In a shorter period, this newly emergent infection bought the world into a standstill. On 11th March 2020, WHO declared COVID-19 as a pandemic. The researchers across the globe have joined their hands to investigate about SARSCoV2 in terms of pathogenicity, transmissibility and deduce therapeutics to subjugate this infection. T The researchers and scholars practicing different art of medicine are into an extensive quest to come up with safer ways to curb the pathological implications of this viral infection. A huge number of clinical trials are underway from the branch of allopathy and naturopathy in this regard. Besides, a paradigm shift on cellular therapy and nano-medicine protocols have to be optimized for better clinical and functional outcome of COVID-19 affected individuals. This article unveils a comprehensive review of the pathogenesis, mode of spread and various treatment modalities to combat COVID-19 disease.Funding: National Natural Science Foundation of China.Conflict of Interest: We declare no competing interests.